Medical Cannabis

CPH’s US listing is happening tonight - trading as OTC: COPHF

Next Investors Jun 11, 2021

Creso Pharma (ASX:CPH) today announced its listing in the US, and the market is opening in around 12 hours - the US pool of investors is huge and they have a big appetite for psychedelics and cannabis stocks.

CPH set to expand in $300M Latin American CBD market

Finfeed Archived Jun 04, 2021

The expansion of its comprehensive distribution agreement with leading nutritional supplements company Route2 Pharm Pvt Ltd, will allow for distribution of Creso Pharma Limited's (ASX: CPH, FRA: 1X8) hemp derived therapeutic products sold under the cannaQIX® and CannaDOL brands into Ecuador.

Bod Australia continues to break sales records

Finfeed Archived May 10, 2021

Bod Australia (ASX: BDA) today announced its highest ever monthly sales for its medicinal cannabis prescription products. BDA attributes its current growth to its Australia wide clinical study to test the efficacy of MediCabilis™ when prescribed for conditions including anxiety, insomnia, and Post Traumatic Stress Disorder (PTSD).

Can BDA’s medical cannabis product treat long-COVID symptoms?

Finfeed Archived Mar 18, 2021

Bod Australia Limited (ASX: BDA) has entered into a collaboration agreement with the UK’s leading independent scientific body on drugs, Drug Science UK, which has the potential to unlock a large market opportunity for BDA in the treatment of long-term symptoms of COVID-19.

SURPRISE: We are Now Psychedelics Investors

Next Investors Mar 15, 2021

Once again, medicinal cannabis company Creso Pharma (ASX: CPH) keeps pleasantly surprising us. Today they have REALLY surprised us by announcing they have acquired a Psychedelics company.

Creso enters the growing CBD market in sport and recreation

Finfeed Archived Mar 09, 2021

Today, Creso Pharma Limited (ASX:CPH, FRA:1X8) announced a Letter of Interest (LOI) which marks its entry into the CBD market for sport and recreation; an industry whose global valuation is estimated at US$22Bn by 2022 and C$220m in Canada alone.

CPH deliver Financials and Confirms US Cannabis Market Entry

Next Investors Mar 01, 2021

Creso Pharma (ASX: CPH) just released its preliminary financial reports for the year, which as expected show a bunch of impairments, debt clean ups and other scary looking one off costs that come with a balance sheet clean up - these are all out of the way now.

Neurotech’s key near-term objectives

Finfeed Archived Jan 21, 2021

Neurotech International Limited (ASX: NTI) has provided a comprehensive overview and update regarding the company’s cannabis strains, development strategy and some of the key near-term objectives expected to be delivered.

NTI Complete In Vitro Studies on Cannabis Strains, Clinical Trials Await

Finfeed Archived Dec 21, 2020

Neurotech International Ltd (ASX: NTI) has today confirmed the successful completion of in-vitro studies using human brain cells to assess and validate the anti-inflammatory and neuro-modulatory properties of its proprietary DOLCE/NTI cannabis leads.

Page 1 of 2 next >